Overview

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Status:
Completed

Trial end date:
2001-11-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation from a brother or sister may be effective treatment for hematologic cancer. Sometimes the transplanted cells can be rejected by the body's tissue. Mycophenolate mofetil, tacrolimus, and donor white blood cells may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of mycophenolate mofetil, tacrolimus, daclizumab, and donor peripheral stem cell transplantation in treating patients who have hematologic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Maryland Greenebaum Cancer Center
University of Maryland, Baltimore

Treatments:

Daclizumab
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus